Louisiana

Overview

Louisiana operates a physician-recommendation-based medical cannabis program under the Therapeutic Use of Marijuana Act (HB 149 of 2015, signed by Governor Bobby Jindal on June 30, 2015). Medical dispensing began August 6, 2019. The 2020 expansion via HB 819 removed the original narrow enumerated condition list and replaced it with broad physician discretion. Louisiana decriminalized small-amount possession in 2021.

The 2026 legislative session has two significant bills under consideration: HB 373 would launch a three-year adult-use pilot program allowing approved medical dispensaries to opt into adult-use sales in designated health districts; HB 568 would impose mandatory jail time for cannabis consumption within 2,000 feet of a school or on a school bus.

Medical program

Physician-discretion qualifying

Since HB 819 (2020), Louisiana physicians may recommend medical cannabis for any condition the physician "considers debilitating to an individual patient." The non-exhaustive list of qualifying conditions identified in legislative history includes:

• Cancer, ALS, Parkinson's, Alzheimer's, MS, HIV/AIDS, epilepsy
• Crohn's disease, inflammatory bowel disease
• Glaucoma, autism, PTSD
• Chronic pain
• Terminal illness, hospice-care patients
• Traumatic brain injury, neurodegenerative diseases

Patients do not require state-issued medical cards (a physician's written recommendation is sufficient documentation).

Product forms and limits

• Approved forms: tinctures, oils, gummies, capsules, topicals, vaporization, raw plant / flower (added 2022).
• Home cultivation: prohibited.
• Reciprocity: out-of-state cards may be honored at dispensary discretion; verify with the dispensary.

Recreational status

Possession of under 14 grams was decriminalized effective August 1, 2021 via HB 652. Penalty for first and subsequent offenses: $100 fine, no jail time. Possession of larger amounts remains criminal under La. R.S. 40:966, with felony penalties for substantial quantities.

Patients and caregivers

• Patient minimum age: no statutory floor. Minor patients require a parent or legal guardian as designated caregiver.
• Caregiver minimum age: 21.
• Caregiver registration: via Louisiana Board of Pharmacy; background check.

The caregiver framework primarily addresses pediatric patients, adults with severe disabilities, and hospice patients who cannot themselves obtain product from a therapeutic-marijuana pharmacy. A caregiver may pick up product on behalf of a registered patient but cannot consume product themselves under the caregiver authorization.

Licensed therapeutic marijuana pharmacies

The Louisiana Board of Pharmacy licenses a limited number of therapeutic marijuana pharmacies, distributed roughly by region. Cultivation is restricted to two state-authorized growers: LSU AgCenter (partnered with Wellcana) and Southern University AgCenter (partnered with Ilera Holistic Healthcare). The university-affiliated cultivation framework is unique to Louisiana and reflects the original 1991 enabling statute that designated the two land-grant institutions as sole cultivators.

Pharmacy operations:

• Dispensing: by licensed pharmacists subject to professional review of the physician recommendation.
• Patient verification: physician written recommendation or out-of-state medical card (at dispensary discretion).
• Payment: debit cards generally accepted; major credit cards typically not; cash always accepted.

Reciprocity and visiting patients

Louisiana provides discretionary (not statutory) reciprocity. Out-of-state patients may purchase from licensed Louisiana therapeutic marijuana pharmacies at the pharmacy's discretion under Louisiana Board of Pharmacy guidance. There is no formal statewide reciprocity guarantee. Visitors should call the specific pharmacy in advance to confirm acceptance of their home-state medical card and any required documentation.

Out-of-state cards do not protect against possession charges for cannabis brought into Louisiana from another state. Reciprocity functions as a purchase-only accommodation: the patient must buy from a Louisiana pharmacy under Louisiana rules.

Employment and workplace

Louisiana law provides limited employment protection for registered medical cannabis patients. La. R.S. 40:1046 prohibits employers from discriminating against an employee or applicant solely because of the person's status as a medical cannabis patient, but does not prohibit discipline for on-the-job impairment or for safety-sensitive positions.

The protection has significant carve-outs:

• Safety-sensitive positions: employers may continue to enforce drug-free workplace policies for safety-sensitive roles as defined by the employer.
• Federal contractor and DOT-regulated positions: federal drug-free workplace and DOT testing rules supersede state-level patient protection.
• Healthcare licensing: state licensing boards retain authority to discipline licensees for cannabis use, including off-duty medical use.

Workers' compensation rules and post-incident testing continue to apply. A positive THC test following a workplace accident may still result in benefit denial unless the patient can demonstrate compliance with medical use parameters at the time of the incident.

Hemp-derived intoxicants

Louisiana enacted significant restrictions on hemp-derived consumable cannabinoids through Act 498 of 2024, which capped total THC per serving and per package, imposed a 21-and-over purchase age, mandated testing and labeling, and prohibited synthetic cannabinoid analogs. Enforcement is by the Louisiana Office of Alcohol and Tobacco Control. The 2026 session has considered further restrictions on delta-8 THC, delta-10 THC, and similar compounds.

Recent legislative history

The Louisiana medical program has expanded incrementally since 2015:

• 2015: HB 149 enacts the Therapeutic Use of Marijuana Act (narrow enumerated conditions).
• 2019: Medical dispensing begins August 6.
• 2020: HB 819 replaces enumerated conditions with broad physician discretion.
• 2021: HB 652 decriminalizes small-amount possession; HB 391 authorizes raw flower as a dispensable form (effective January 2022).
• 2022: Raw flower sales begin.
• 2024: Act 498 restricts hemp-derived intoxicating cannabinoids.
• 2026: HB 373 (adult-use pilot in designated health districts) and HB 568 (mandatory jail time for school-zone consumption) under consideration.

The April 2026 federal Schedule III rescheduling order was cited by HB 373 sponsors as supportive context for the adult-use pilot proposal.

Federal context

Federal jurisdiction layers additional exposure on federal land, federal courthouses, military installations (Barksdale Air Force Base, Fort Johnson, NAS JRB New Orleans), and interstate highways. I-10, I-12, I-20, I-49, and I-55 corridors see active state-patrol and federal interdiction activity, particularly at the Texas, Mississippi, and Arkansas borders. Louisiana State Police participates in federal drug-task-force operations along the I-10 corridor.